The FA pathway has been associated with PARP inhibitor resistance in head and neck cancers [32], and the overexpression of FANCD2 confers PARP inhibitor resistance in BRCA1/2 mutant breast cancer cells [33]. Here, FANCD2 is linked to breast cancer.